Tau Biology and Tau-Directed Therapies for Alzheimer's Disease

DC FieldValueLanguage
dc.contributor.authorBakota, Lidia
dc.contributor.authorBrandt, Roland
dc.date.accessioned2021-12-23T16:02:22Z-
dc.date.available2021-12-23T16:02:22Z-
dc.date.issued2016
dc.identifier.issn00126667
dc.identifier.urihttps://osnascholar.ub.uni-osnabrueck.de/handle/unios/5377-
dc.description.abstractAlzheimer's disease (AD) is characterised by a progressive loss of cognitive functions. Histopathologically, AD is defined by the presence of extracellular amyloid plaques containing Ab and intracellular neurofibrillary tangles composed of hyperphosphorylated tau proteins. According to the now well-accepted amyloid cascade hypothesis is the Ab pathology the primary driving force of AD pathogenesis, which then induces changes in tau protein leading to a neurodegenerative cascade during the progression of disease. Since many earlier drug trials aiming at preventing Ab pathology failed to demonstrate efficacy, tau and microtubules have come into focus as prominent downstream targets. The article aims to develop the current concept of the involvement of tau in the neurodegenerative triad of synaptic loss, cell death and dendritic simplification. The function of tau as a microtubule-associated protein and versatile interaction partner will then be introduced and the rationale and progress of current tau-directed therapy will be discussed in the biological context.
dc.description.sponsorshipDeutsche Forschungsgemeinschaft (DFG)German Research Foundation (DFG) [BR1192/11-2]; Alzheimer Foschungsinitiative e.V. (AFI); Funds have been provided by the Deutsche Forschungsgemeinschaft (DFG BR1192/11-2; to R.B.) and the Alzheimer Foschungsinitiative e.V. (AFI; to L.B.).
dc.language.isoen
dc.publisherADIS INT LTD
dc.relation.ispartofDRUGS
dc.subjectA-BETA
dc.subjectAGGREGATION INHIBITOR THERAPY
dc.subjectAMYLOID-BETA
dc.subjectCOGNITIVE DEFICITS
dc.subjectDENDRITIC SPINE ALTERATIONS
dc.subjectMICROTUBULE-STABILIZING AGENT
dc.subjectPAIRED HELICAL FILAMENTS
dc.subjectPASSIVE-IMMUNIZATION
dc.subjectPharmacology & Pharmacy
dc.subjectPROTEIN PHOSPHATASE 2A
dc.subjectToxicology
dc.subjectTRANSGENIC MOUSE MODEL
dc.titleTau Biology and Tau-Directed Therapies for Alzheimer's Disease
dc.typejournal article
dc.identifier.doi10.1007/s40265-015-0529-0
dc.identifier.isiISI:000372531800002
dc.description.volume76
dc.description.issue3
dc.description.startpage301
dc.description.endpage313
dc.contributor.orcid0000-0002-8777-5006
dc.contributor.orcid0000-0003-0101-1257
dc.identifier.eissn11791950
dc.publisher.place5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
dcterms.isPartOf.abbreviationDrugs
dcterms.oaStatusGreen Published, hybrid
crisitem.author.orcid0000-0003-0101-1257-
crisitem.author.netidBrRo587-
Show simple item record

Page view(s)

3
Last Week
0
Last month
0
checked on Apr 17, 2024

Google ScholarTM

Check

Altmetric